Seelos Therapeutics, Inc. SEEL shares are trading higher after Guggenheim analyst Yatin Suneja initiated coverage on the stock with a Buy rating and announced an $8 price target.
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders.
Seelos shares were trading about 7.8% higher at $2.85 on Thursday. The stock has a 52-week high of $6.60 and a 52-week low of $0.56.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
